Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Munich - Delayed Quote EUR

Alnylam Pharmaceuticals Inc (DUL.MU)

Compare
232.30
-1.20
(-0.51%)
At close: February 28 at 5:26:30 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,248,243
2,248,243
1,828,292
1,037,418
844,287
Cost of Revenue
323,370
323,370
310,406
168,817
140,144
Gross Profit
1,924,873
1,924,873
1,517,886
868,601
704,143
Operating Expense
2,101,758
2,101,758
1,800,061
1,653,673
1,412,795
Operating Income
-176,885
-176,885
-282,175
-785,072
-708,652
Net Non Operating Interest Income Expense
-19,866
-19,866
-25,660
-131,160
-141,442
Other Income Expense
-180,624
-180,624
-125,682
-210,761
-2,050
Pretax Income
-377,375
-377,375
-433,517
-1,126,993
-852,144
Tax Provision
-99,218
-99,218
6,725
4,163
680
Net Income Common Stockholders
-278,157
-278,157
-440,242
-1,131,156
-852,824
Diluted NI Available to Com Stockholders
-278,157
-278,157
-440,242
-1,131,156
-852,824
Basic EPS
-2.18
--
-3.52
-9.30
-7.20
Diluted EPS
-2.18
--
-3.52
-9.30
-7.20
Basic Average Shares
127,651
--
124,906
121,689
118,451
Diluted Average Shares
127,651
--
124,906
121,689
118,451
Total Operating Income as Reported
-176,885
-176,885
-282,175
-785,072
-708,652
Rent Expense Supplemental
169,909
169,909
145,687
131,967
97,259
Total Expenses
2,425,128
2,425,128
2,110,467
1,822,490
1,552,939
Net Income from Continuing & Discontinued Operation
-278,157
-278,157
-440,242
-1,131,156
-852,824
Normalized Income
-150,057.73
-150,057.73
-354,968.61
-969,555.97
-865,425.26
Interest Income
121,992
121,992
95,561
24,808
1,579
Interest Expense
141,858
141,858
121,221
155,968
143,021
Net Interest Income
-19,866
-19,866
-25,660
-131,160
-141,442
EBIT
-235,517
-235,517
-312,296
-971,025
-709,123
EBITDA
-178,847
-178,847
-215,265
-885,475
-619,429
Reconciled Cost of Revenue
323,370
323,370
310,406
168,817
140,144
Reconciled Depreciation
56,670
56,670
97,031
85,550
89,694
Net Income from Continuing Operation Net Minority Interest
-278,157
-278,157
-440,242
-1,131,156
-852,824
Total Unusual Items Excluding Goodwill
-173,792
-173,792
-107,941
-204,557
17,262
Total Unusual Items
-173,792
-173,792
-107,941
-204,557
17,262
Normalized EBITDA
-5,055
-5,055
-107,324
-680,918
-636,691
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-45,692.73
-45,692.73
-22,667.61
-42,956.97
4,660.74
12/31/2021 - 2/5/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

APRE Aprea Therapeutics, Inc.
2.5336
+0.14%
 
RKVTF RAKOVINA THERAPEUTICS INC
0.0920
0.00%
 
SLXNW Silexion Therapeutics Corp
0.0600
-13.42%
 
GALT Galectin Therapeutics Inc.
1.5700
+6.08%
 
RKV.V Rakovina Therapeutics Inc.
0.1400
-12.50%
 
INKT MiNK Therapeutics, Inc.
8.95
-2.72%
 
TECX Tectonic Therapeutic, Inc.
25.28
-1.13%
 
ABSI Absci Corporation
3.8500
-4.70%
 
SANA Sana Biotechnology, Inc.
2.6100
+0.77%
 
KZIA Kazia Therapeutics Limited
0.8514
+1.36%